Lineage Cell Therapeutics, Inc. Quarterly Entity Common Stock, Shares Outstanding from Q2 2011 to Q3 2024

Taxonomy & unit
dei: shares
Description
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
Summary
Lineage Cell Therapeutics, Inc. quarterly Entity Common Stock, Shares Outstanding history and growth rate from Q2 2011 to Q3 2024.
  • Lineage Cell Therapeutics, Inc. Entity Common Stock, Shares Outstanding for the quarter ending November 8, 2024 was 189M shares, a 7.92% increase year-over-year.
Entity Common Stock, Shares Outstanding, Quarterly (shares)
Entity Common Stock, Shares Outstanding, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 189M +13.9M +7.92% Nov 8, 2024 10-Q 2024-11-14
Q2 2024 189M +13.9M +7.92% Aug 2, 2024 10-Q 2024-08-08
Q1 2024 189M +18.4M +10.8% Mar 1, 2024 10-K 2024-03-07
Q3 2023 175M +5.01M +2.95% Nov 3, 2023 10-Q 2023-11-09
Q2 2023 175M +5.23M +3.08% Aug 4, 2023 10-Q 2023-08-10
Q1 2023 170M +464K +0.27% Apr 26, 2023 10-K/A 2023-04-27
Q3 2022 170M +1.42M +0.84% Nov 4, 2022 10-Q 2022-11-10
Q2 2022 170M +2.3M +1.37% Aug 5, 2022 10-Q 2022-08-11
Q1 2022 170M +8.07M +4.99% Mar 4, 2022 10-K 2022-03-10
Q3 2021 169M +18.6M +12.4% Nov 5, 2021 10-Q 2021-11-10
Q2 2021 167M +17.5M +11.7% Aug 6, 2021 10-Q 2021-08-12
Q1 2021 162M +11.8M +7.9% Mar 5, 2021 10-K 2021-03-11
Q3 2020 150M +197K +0.13% Nov 3, 2020 10-Q 2020-11-04
Q2 2020 150M +338K +0.23% Aug 5, 2020 10-Q 2020-08-06
Q1 2020 150M +447K +0.3% Mar 5, 2020 10-K 2020-03-12
Q3 2019 150M +22.8M +18% Nov 8, 2019 10-Q 2019-11-12
Q2 2019 150M +22.8M +17.9% Aug 6, 2019 10-Q 2019-08-08
Q1 2019 149M +22.5M +17.7% Mar 11, 2019 10-K 2019-03-14
Q3 2018 127M +98.4K +0.08% Nov 7, 2018 10-Q 2018-11-08
Q2 2018 127M +11.1M +9.56% Jul 23, 2018 10-Q 2018-08-02
Q1 2018 127M +16M +14.4% Mar 13, 2018 10-K 2018-03-15
Q3 2017 127M +23.5M +22.7% Nov 1, 2017 10-Q 2017-11-09
Q2 2017 116M +12.4M +12% Aug 9, 2017 10-Q 2017-08-09
Q1 2017 111M +16M +16.8% Mar 9, 2017 10-K 2017-03-16
Q3 2016 103M +8.5M +8.96% Oct 13, 2016 10-Q 2016-11-04
Q2 2016 103M +20.1M +24.1% Aug 5, 2016 10-Q 2016-08-09
Q1 2016 94.9M +11.7M +14.1% Mar 4, 2016 10-K 2016-03-15
Q3 2015 94.9M +11.8M +14.2% Nov 6, 2015 10-Q 2015-11-09
Q2 2015 83.3M +9.59M +13% Aug 3, 2015 10-Q 2015-08-10
Q1 2015 83.2M +13.6M +19.5% Mar 9, 2015 10-K 2015-03-11
Q3 2014 83.1M +15.9M +23.7% Nov 5, 2014 10-Q 2014-11-07
Q2 2014 73.7M +15.8M +27.2% Aug 6, 2014 10-Q 2014-08-11
Q1 2014 69.6M +14.7M +26.8% Mar 5, 2014 10-K 2014-03-17
Q3 2013 67.2M +16.3M +32.1% Nov 8, 2013 10-Q 2013-11-12
Q2 2013 57.9M +7.07M +13.9% Aug 7, 2013 10-Q 2013-08-09
Q1 2013 54.9M +4.58M +9.11% Mar 14, 2013 10-K 2013-03-18
Q3 2012 50.9M +621K +1.24% Oct 23, 2012 10-Q 2012-11-09
Q2 2012 50.9M +2M +4.09% Aug 7, 2012 10-Q 2012-08-09
Q1 2012 50.3M Mar 5, 2012 10-K 2012-03-14
Q3 2011 50.2M Oct 31, 2011 10-Q 2011-11-08
Q2 2011 48.9M Jul 19, 2011 10-Q 2011-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.